The DOI matches its Crossref record; 59 of the 60 references it cites were found in a registry or an index.
Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis
Open accessAbstract
CD8(+) T cells recognizing tumor-specific antigens are detected in cancer patients but are dysfunctional. Here we developed a tamoxifen-inducible liver cancer mouse model with a defined oncogenic driver antigen (SV40 large T-antigen) to follow the activation and differentiation of naive tumor-specific CD8(+) T (TST) cells after tumor initiation. Early during the pre-malignant phase of tumorigenesis, TST cells became dysfunctional, exhibiting phenotypic, functional, and transcriptional features similar to dysfunctional T cells isolated from late-stage human tumors. Thus, T cell dysfunction seen in advanced human cancers may already be established early during tumorigenesis. Although the TST cell dysfunctional state was initially therapeutically reversible, it ultimately evolved into a fixed state. Persistent antigen exposure rather than factors associated with the tumor microenvironment drove dysfunction. Moreover, the TST cell differentiation and dysfunction program exhibited features distinct from T cell exhaustion in chronic infections. Strategies to overcome this antigen-driven, cell-intrinsic dysfunction may be required to improve cancer immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Profiling adoptively transferred SV40 large T cell antigen (Tag+)–specific CD8+ T cells indicated that Tag+ T cells followed classic signs of exhaustion upon entry into the tumor-bearing livers (fig. S2D) (19).”
From Bile acid synthesis impedes tumor-specific T cell responses during liver cancer (2025) · cites this paper as [19]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Conversely, terminal Tex (Ttex) cells accumulate over time and respond poorly to ICB therapies8,11–13.”
From Proteotoxic stress response drives T cell exhaustion and immune evasion (2025) · cites this paper as [13]
Experimental — accuracy not yet measuredIn the citing paper
“Indeed, the T cell immune response to HCC antigens is reportedly dysfunctional and unreactive to HCC55.”
From Tumor-specific cholinergic CD4+ T lymphocytes guide immunosurveillance of hepatocellular carcinoma (2023) · cites this paper as [55]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 1×
“…studies have demonstrated that blocking inhibitory receptors (checkpoint blockade) can mediate functional rescue of unresponsive T cells in chronic infection or tumors (Barber et al., 2006; Brahmer et al., 2012; Perez-Gracia et al., 2014; (A) Tamoxifen (Tam)-inducible ASTxCre-ERT2 tumor model.”
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
Tumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2005) · Nature · doi:10.1038/nature04444 · Cited by 4,057
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544
T cell receptor antagonist peptides induce positive selection.
Hogquist, K., Jameson, S., Heath, W., Howard, J. L., Bevan, M., & Carbone, F. (1994) · Cell · doi:10.1016/0092-8674(94)90169-4 · Cited by 3,252
Flagged first, then by citations
1 of the 60 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 701–726 of 726
Rôle de Programmed cell Death-Ligand 1 dans la progression du carcinome hépatocellulaire
Rousseau, B. (2021) · theses.fr (ABES) · doi:10.70675/dd181429zd664z4681zbe04z06271b5e1f39
Spatiotemporal profiling reveals the role of inflammatory niche in driving prostate cancerPreprint
Nazir, A., Wang, H., Lu, Z., Lau, J., Peale, F., Jesudason, R., Connolly, K. A., Andrusivová, Ž., Lau, J., Gierke, S., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.19.719485
Mukohara, F. (2026) · Okayama Igakkai Zasshi (Journal of Okayama Medical Association) · doi:10.4044/joma.138.7
Barbao, P., Rodríguez-García, A., Galindo‐Albarrán, A., Giménez-Alejandre, M., Clavero, P., Lobo‐Jarne, T., Botas, M., Colell, G., Castellsagué, J., Cascalló, G., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.30.721530 · Cited by 1
Alatrash, R., Iyer, S., & Herrera, B. B. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.18.725972
Aleynick, M., Wang, Q., Wu, J. E., Lemus, S., Chaimowitz, M. G., Mir, H., Warsaw, J. J., Guo, C., Macdonald, L. E., Waite, J. C., et al. (2026) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-25-1420
Zhang, W., Yuan, W., Yuan, C., Cheng, Y., Zhang, D., Cao, X., & Ding, C. (2026) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2026.06.004
Tumor-driven stabilization of CD8+ T cell exhaustion and implications for cancer immunotherapy
Thouenon, R., Ongaro, M., & Verdeil, G. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1862431
de Graça, C. G., Cao, Y., Li, S. F., Lindemann, A. F., Heyden, L., Wijesinghe, S. K. M., Poch, A., Nguyen, M.-H. T., Huynh-Anh, N. T., Daum, E., et al. (2026) · Immunity · doi:10.1016/j.immuni.2026.06.003
Tumor infiltrating lymphocytes in glioblastoma: immunobiology and translational implications
Hill, C. M., Nwagwu, C. D., Odukoya, A. O., Hsueh, B., Wang, A. Z., & Dunn, G. P. (2026) · npj Precision Oncology · doi:10.1038/s41698-026-01330-3
Epigenetic-targeted nanomedicine in cancer: from molecular mechanisms to therapeutic revolution
Wang, B., Han, Y., Zhang, X., Li, Y., Cai, Z., Duan, Z., Gong, Q. H., Jiang, Y., & Luo, K. (2026) · Progress in Materials Science · doi:10.1016/j.pmatsci.2026.101789
Targeting the fate of exhausted CD8+ T cells
Utzschneider, D. T., & Turner, S. T. (2026) · Trends in Immunology · doi:10.1016/j.it.2026.07.002 · Cited by 1
Silvane, L., Ζελένκα, Τ., Talada, D. P., Cismasiu, V. B., Islam, S., Singh, R. P., Ngove, Z., Chakraborty, S., Hall, M. S., Blauvelt, J. L., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.03.742578
Aggarwal, V., Sun, Y., Liu, C., Cui, J., Manne, S., Dou, Y., Chen, Q., Brunazzi, E. A., Vignali, K. M., Wang, H., et al. (2026) · The Journal of Experimental Medicine · doi:10.1084/jem.20241968
Micrometastasis as a distinct immunobiological state and therapeutic target
Avalle, S., & Celià-Terrassa, T. (2026) · Trends in Immunology · doi:10.1016/j.it.2026.07.010
Awad, S., Calagua, C., Voznesensky, O. S., Abdelkader, S., Mohanna, R., Kissick, H., Signoretti, S., Einstein, D. J., & Balk, S. P. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.27.747524
Mechanisms of Immune Cell Dysregulation in Pancreatic Ductal Adenocarcinoma
Ahmady, F., Luwor, R. B., & Kannourakis, G. (2026) · Biology · doi:10.3390/biology15181599 · Cited by 1
Cytokine-mediated activation of exhausted T cellsPreprint
Goljat, E., Daetwyler, R., Yassini, N., Rakebrandt, N., Li, Z., Quintana, F. J., & Joller, N. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.28.755149
Immune‐Cell Dynamics in the Tumor Microenvironment: Implications for Cancer Therapy
Pin, G., Xie, Y., Song, R., Yang, M., Lin, Z., Guan, C., Wang, Z., Wen, J., & Chen, G. (2026) · MedComm · doi:10.1002/mco2.71040
A preinvasive regulatory T cell axis for lung cancer interception
Gamble, S., Whiteman, Z. E., Marin, C. P., Lebrusant‐Fernandez, M., Shurr, A. Y. L., Enica, A., Sahwangarrom, T., Ung, S. K. A., Rogers, A., Fessas, P., et al. (2026) · Nature · doi:10.1038/s41586-026-11066-6
CRISPR-Cas9 screen identifies eIF4G2 as a regulator of CD8+ T cell dysfunction
Holcomb, E. A., Jiang, L., Pearson, A. N., James, J., Tate, A., Wang, Z., Dasgupta, A., Clauwaert, J., Armas, N. D., Elaimy, A. L., et al. (2026) · The Journal of Immunology · doi:10.1093/jimmun/vkag187
Yang, Z.-K., Li, J., Xu, D.-X., Xu, Q.-Q., Meng, J., Wang, J.-J., Zhang, B., Dai, J.-C., Zhang, Y., Pu, Z.-N., et al. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.117540
Beyond Exhaustion: The RNA Regulatory Layer of Tissue‐Instructed T Cell Dysfunction
Andreata, F., Marasca, F., Bodega, B., & Iannacone, M. (2026) · European Journal of Immunology · doi:10.1002/eji.70286
From dysfunction to differentiation: a new paradigm of T cell exhaustion
Stepanova, V. M., Logvinov, A., Emelyanov, E. A., Katin, N. A., & Rubtsov, Y. P. (2026) · Acta Naturae · doi:10.32607/actanaturae.27873
Metadata
- Authors
- Schietinger, A., Philip, M., Krisnawan, V. E., Chiu, E. Y., Delrow, J. J., Basom, R. S., Lauer, P., Brockstedt, D. G., Knoblaugh, S. E., Hämmerling, G. J., Schell, T. D., Garbi, N., & Greenberg, P. D.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- University of Washington (US)
- Fred Hutch Cancer Center (US)
- Aduro BioTech (United States) (US)
- German Cancer Research Center (DE)
- Pennsylvania State University (US)
- University of Bonn (DE)
- Corresponding author
- Schietinger, Andrea
- Greenberg, Philip D.
- ORCID
- Venue
- Immunity
- Publisher
- Elsevier BV
- Published
- 2016-08
- Volume
- 45
- Issue
- 2
- Pages
- 389-401
- ISSN
- 1074-7613 (ISSN-L)
- PMC
- PMC5119632
- OpenAlex
- W2514996992
- Cited by
- 720
- References
- 60
- Citations by year
- 2026: 45 · 2025: 77 · 2024: 93 · 2023: 84 · 2022: 78 · 2021: 103 · 2020: 99 · 2019: 61 · 2018: 50 · 2017: 25 · 2016: 5
- FWCI
- 25.49
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Immunity (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R00CA172371, K99CA172371, K08CA158069, R01CA033084, P30CA008748, P30CA015704)
- National Institute of Allergy and Infectious Diseases (R21AI107776)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- tumor-specific T cells, CD8+ T cell dysfunction, carcinogenesis, SV40 large T antigen, liver cancer, T cell differentiation, T cell exhaustion, cancer immunotherapy
- MeSH terms
- Animals, Antigens, Polyomavirus Transforming, Cell Differentiation, Cells, Cultured, Disease Models, Animal, Humans, Liver Neoplasms, Lymphocyte Activation, Mice, Inbred C57BL, Mice, Transgenic, Tamoxifen, Immunotherapy, Adoptive, Cellular Senescence, CD8-Positive T-Lymphocytes, Cancer Vaccines, Mice, Tumor Microenvironment, Carcinogenesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
